Calculate pediatric dosages for Bethanechol in seconds with our Bethanechol pediatric dosing calculator. Input the details, press Calculate Dosage, and get precise Bethanechol prescriptions for every child!
Bethanechol is a cholinergic agonist used to improve bladder emptying in children with non-obstructive urinary retention.
Confirm neurogenic or functional etiology via urodynamics; bethanechol is not effective for outlet obstruction or vesicoureteral reflux alone.
Start with low doses (0.2 mg/kg three times daily) and titrate based on residual volumes while monitoring for cholinergic adverse effects (sweating, bronchospasm, abdominal cramps).
Coordinate therapy with intermittent catheterization, anticholinergics, or botulinum toxin as indicated; reassess necessity once bladder capacity and compliance improve.
Avoid in asthma, hyperthyroidism, bradycardia, or gastrointestinal obstruction; these comorbidities increase risk of adverse events.
Educate caregivers on early signs of cholinergic toxicity and provide an action plan to hold medication and seek care if they appear.
Long-term benefit should be evaluated at regular urology visits with post-void residuals and renal/bladder ultrasound.
Bethanechol is reserved for specific urologic indications.
Primary use is non-obstructive urinary retention; careful selection prevents adverse events.
| Condition | Age Range | First Line? | Notes |
|---|---|---|---|
| Non-obstructive urinary retention | Children with hypotonic or neurogenic bladder | Yes | Use under pediatric urology guidance after excluding mechanical obstruction; titrate in conjunction with intermittent catheterization programs. |
| Detrusor areflexia from spinal cord or myelomeningocele | Pediatric patients in structured bladder rehabilitation | Yes | Adjunct to catheterization schedules to enhance detrusor tone when residuals remain elevated. |
| Gastroparesis or severe GERD (historic use) | Selected infants and children | No | Occasionally considered when prokinetic support is needed and modern agents have failed; evidence is limited and cholinergic adverse effects restrict use. |
FDA-approved primary uses with Level A evidence
Quick selection guides and diagnostic pearls
When to consider other medications
How to explain treatment to families
Bethanechol’s muscarinic agonist activity can trigger predictable cholinergic effects; proactive monitoring prevents complications.
Mild gastrointestinal cramps, nausea, and sweating are common. Serious but uncommon reactions include bronchospasm, bradycardia, or hypotension, especially in children with asthma or cardiac disease.
Abdominal cramps/diarrhea
Common • mild
Nausea/vomiting
Common • mild
Bronchospasm/wheezing
Rare • serious
Bradycardia/hypotension
Rare • serious
Headache or dizziness
Uncommon • mild
Organized by affected organ systems
How to discuss side effects with families
Management protocols and monitoring
Common concerns and practical guidance
Administration notes for bethanechol.
Give on an empty stomach, one hour before or two hours after meals to avoid nausea. Use the dosing schedule prescribed by the urologist.
Monitor urinary output records, especially when toilet training or using intermittent catheterization. Avoid evening doses if nighttime urinary urgency is problematic unless instructed.
Emergency contact: Seek urgent care for wheezing, severe abdominal cramps, slow heart rate, or excessive sweating and salivation.
Never double doses. Inform clinicians about asthma, peptic ulcers, or low blood pressure before starting.
Different formulations and concentrations
Safe preparation and measuring techniques
Tailored approaches for different ages
Solutions for common challenges
Storage guidelines and safety tips
Expert pearls and evidence-based tips
Bethanechol is a direct-acting parasympathomimetic that selectively stimulates muscarinic receptors in smooth muscle, restoring coordinated bladder emptying when detrusor tone is inadequate.
As a quaternary ammonium choline ester, bethanechol resists hydrolysis by acetylcholinesterase and has negligible nicotinic activity. Its primary clinical effect is sustained activation of M3 receptors on detrusor muscle, which increases bladder pressure and lowers outlet resistance to facilitate voiding in children with neurogenic or postoperative urinary retention.
Simple explanations and helpful analogies
Receptors, enzymes, and cellular targets
Absorption, metabolism, and elimination
Age-related differences and special populations
Bethanechol can be transformative for carefully selected children with underactive bladder. These pearls emphasize safe initiation, coordination with pelvic floor therapy, and vigilant monitoring for cholinergic effects.
Pair bethanechol with behavioral regimens, document objective gains, and taper promptly if cholinergic adverse effects emerge.
Obtain a bladder scan, uroflow/EMG, or catheterization to document detrusor underactivity before prescribing bethanechol…
Begin at 0.5 mg/kg/day divided q6h and increase every 5–7 days only if voiding diaries and residuals demonstrate improve…
Bethanechol works best when scheduled voiding or clean intermittent catheterization reinforces bladder cycling and prote…
Advise families to administer with food or milk and to report severe abdominal pain, diarrhea, or hypersalivation prompt…
Core insights every provider should know
+4 more pearls...
Recent updates that change how we practice
Organized by dosing, administration, and safety
How to explain treatments to families
Real-world cases with evidence-based approaches
Key numbers, algorithms, and decision tools
Understanding your child's medication is important. We've created comprehensive guides to help you safely administer Bethanechol and monitor your child's response to treatment.
Some children respond within several days, but full benefit may take a few weeks of scheduled voiding and pelvic floor therapy. Keep a bladder diary to share with your clinician.
Yes. Mild sweating, warmth, or flushing is common. Call if symptoms become excessive or are accompanied by dizziness, wheezing, or severe drooling.
If vomiting occurs within 30 minutes, contact the clinician for guidance before repeating the dose. Ensure the next scheduled dose is taken with a small snack.
Bethanechol is usually temporary. Clinicians reassess bladder emptying every few months and taper once detrusor tone improves or catheterization programs are successful.